Qiufen Guo Selected Research

Dual Specificity Phosphatase 6

3/2015	Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
8/2013	Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estradiol-induced cell growth in endometrial adenocarcinoma cell.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qiufen Guo Research Topics

Disease

3	Adenocarcinoma 03/2020 - 08/2013
2	Endometrial Neoplasms (Endometrial Cancer) 01/2016 - 03/2015
1	Hypertension (High Blood Pressure) 03/2020
1	Neoplasm Metastasis (Metastasis) 03/2020
1	Neoplasms (Cancer) 03/2020
1	Hand-Foot Syndrome 03/2020
1	Proteinuria 03/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/2020
1	Mucositis 03/2020
1	Endometrial Hyperplasia 03/2015
1	Adenomyosis 05/2014

Drug/Important Bio-Agent (IBA)

2	Dual Specificity Phosphatase 6IBA 03/2015 - 08/2013
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 05/2014 - 08/2013
1	apatinibIBA 03/2020
1	Carboplatin (JM8)FDA LinkGeneric 03/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 03/2020
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2020
1	Mitogen-Activated Protein Kinase 3IBA 01/2016
1	Mitogen-Activated Protein KinasesIBA 01/2016
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2016
1	Progestins (Progestagens)IBA 03/2015
1	Estrogens (Estrogen)FDA Link 03/2015
1	Messenger RNA (mRNA)IBA 05/2014

Therapy/Procedure

2	Therapeutics 03/2020 - 03/2015
1	Brachytherapy 03/2020
1	Drug Therapy (Chemotherapy) 03/2020